| Description | Mocravimod hydrochloride (KRP-203) is an effecitive and orally active agonist of sphingosine 1-phosphate receptor type 1(S1PR1). |
| In vivo | 在mHC不匹配的大鼠心脏同种移植模型中，通过口服给予Mocravimod hydrochloride（0.1及1 mg/kg/day；持续100天）能够延长移植物的存活时间，并减轻慢性排斥反应[1]。Mocravimod hydrochloride也可改善LDL-R(-/-)小鼠的动脉粥样硬化症状[2]。 |
| Synonyms | KRP-203 |
| molecular weight | 480.45 |
| Molecular formula | C24H27Cl2NO3S |
| CAS | 509088-69-1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 95 mg/mL (197.73 mM), Sonication is recommended. |
| References | 1. Potì F, et al. KRP-203, sphingosine 1-phosphate receptor type 1 agonist, ameliorates atherosclerosis in LDL-R 2. Shimizu H, et al. KRP-203, a novel synthetic immunosuppressant, prolongs graft survival and attenuates chronicrejection in rat skin and heart allografts. Circulation. 2005 Jan 18;111(2):222-9. Epub 2005 Jan 10. |